Trial abstracts in the registry — page 5
700 documents of type trial abstract.
Documents
-
Diagnostic accuracy study of Gonadorelin in gh axis over single test. Primary result: An established diagnostic stimulation test. The Institute records that the…
Moderate22 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Single-arm open-label study of Thymalin in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 Sep 2024 -
Observational study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low06 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low31 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Aug 2024 -
Observational, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over up to 12 weeks. The Institute holds no reported primary result for this record and publishes no…
Very low09 Aug 2024 -
Randomised crossover, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Aug 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low01 Aug 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low26 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2024 -
Single-arm open-label study of Semax in cognition over open-label extension of the parent trial. The Institute holds no reported primary result for this record and…
Very low16 Jul 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low15 Jul 2024 -
Single-arm open-label study of Gonadorelin in gh axis over months. Primary result: Effective when delivered by pump at a physiological pulse frequency. Non-pulsatile…
Moderate12 Jul 2024 -
Randomised crossover, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low26 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Jun 2024 -
Phase 1 ascending dose, phase 1 study of Petrelintide in obesity over 16 weeks. Primary result: Weight reduction of approximately 8.6 % at 16 weeks in a phase 1b setting.
Low15 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over 52 weeks. Primary result: A smaller weight effect than in…
Low08 Jun 2024 -
Randomised, double-blind, placebo-controlled study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jun 2024 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low30 May 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over 52 weeks. Primary result: A modest effect relative to interferon…
Moderate22 May 2024 -
Observational, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low21 May 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 May 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 May 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 May 2024 -
Randomised withdrawal, phase 3 study of Tirzepatide in obesity randomising 670 participants over 52 weeks after a 36-week open-label lead-in. Primary result: Continued…
High18 May 2024 -
Randomised, open-label, active-controlled, phase 3 study of Liraglutide in type 2 diabetes randomising 464 participants over 26 weeks. Primary result: Difference −0.33…
High18 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low17 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 May 2024 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 May 2024 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 May 2024 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 May 2024
page 5 of 18